Skip to content
Qvanteq
  • Home
  • Technology
    • Key benefits
    • Mechanism of Action
    • Publications
  • Products & Services
    • Neurovascular
    • Peripheral
    • Coronary
    • Other Devices
    • Consulting
  • About us
    • Management
    • Board of Directors
    • Investors
  • News & Media
    • 2021
    • 2020
    • 2019
    • Archive
  • Contact
Qvanteq
  • Home
  • Technology
    • Key benefits
    • Mechanism of Action
    • Publications
  • Products & Services
    • Neurovascular
    • Peripheral
    • Coronary
    • Other Devices
    • Consulting
  • About us
    • Management
    • Board of Directors
    • Investors
  • News & Media
    • 2021
    • 2020
    • 2019
    • Archive
  • Contact
Qvanteq
Qvanteq

Category: 2018

8. October 20188. March 20192018, News

In vitro testing capability with human blood

In collaboration with academic institutions, Qvanteq has developed the capability for dynamic testing of any type of cardiovascular device in a blood loop model (Chandler Loop) using fresh whole human blood. This capability is also available for collaborations.

7. February 20187. February 20182018, News

Qvanteq AG ISO 13485 re-certified

Qvanteq completed ISO13485 re-certification under the guidance of the notified body DEKRA.

Recent News

  • Reduced thrombogenicity of surface-treated Nitinol implants steered by altered protein adsorption
  • Stop the activation of the blood coagulation cascade by your medical device
  • Make any surface antithrombotic
  • Qvanteq is using MedtechVault
  • In-vitro thrombogenicity screening capacity

Qvanteq AG

Technoparkstr. 1, 8005 Zürich, Switzerland
+41 44 500 98 90
info@qvanteq.com

More

  • Meet us
  • Subscribe
  • Contact
  • Disclaimer
Copyright Qvanteq AG